1.
Product Overview
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2.
Research Methodology
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3.
Executive Summary
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. Voice of Customer
5.
Global Direct-acting
Antiviral Drug Market Outlook
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1.
By Type (NS3/4A Protease, NS5A
Protein, NS5B RNA-Dependent RNA polymerase)
5.2.2.
By Indication (Hepatitis C Virus, HIV Infection/ AIDS, Influenza,
Prophylaxis)
5.2.3.
By Route (Intravenous, Oral, Subcutaneous, Topical)
5.2.4.
By Distribution Channel (Hospital Pharmacies, Retail
Pharmacies, Online Pharmacies)
5.2.5. By
Region
5.2.6. By Company (2022)
5.3. Product Market Map
5.3.1. By Drug Type
5.3.2. By Indication
5.3.3. By Route
5.3.4. By Distribution Channel
5.3.5. By Region
6.
North America Direct-acting
Antiviral Drug Market Outlook
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1.
By Type (NS3/4A Protease, NS5A Protein, NS5B
RNA-Dependent RNA polymerase)
6.2.2.
By Indication (Hepatitis C Virus, HIV Infection/ AIDS, Influenza,
Prophylaxis)
6.2.3.
By Route (Intravenous, Oral, Subcutaneous, Topical)
6.2.4. By Distribution Channel (Hospital Pharmacies, Retail
Pharmacies, Online Pharmacies)
6.2.5. By Country
6.3. North America: Country Analysis
6.3.1. United States Direct-acting Antiviral Drug Market Outlook
6.3.1.1.
Market Size &
Forecast
6.3.1.1.1.
By Value
6.3.1.2.
Market Share &
Forecast
6.3.1.2.1.
By Drug Type
6.3.1.2.2.
By Indication
6.3.1.2.3.
By Route
6.3.1.2.4.
By Distribution
Channel
6.3.2. Canada Direct-acting Antiviral Drug Market Outlook
6.3.2.1.
Market Size &
Forecast
6.3.2.1.1.
By Value
6.3.2.2.
Market Share &
Forecast
6.3.2.2.1.
By Drug Type
6.3.2.2.2.
By Indication
6.3.2.2.3.
By Route
6.3.2.2.4.
By Distribution
Channel
6.3.3. Mexico Direct-acting Antiviral Drug
Market Outlook
6.3.3.1.
Market Size &
Forecast
6.3.3.1.1.
By Value
6.3.3.2.
Market Share &
Forecast
6.3.3.2.1.
By Drug Type
6.3.3.2.2.
By Indication
6.3.3.2.3.
By Route
6.3.3.2.4.
By Distribution
Channel
7.
Europe Direct-acting
Antiviral Drug Market Outlook
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1.
By Type (NS3/4A Protease, NS5A Protein, NS5B
RNA-Dependent RNA polymerase)
7.2.2.
By Indication (Hepatitis C Virus, HIV Infection/ AIDS, Influenza,
Prophylaxis)
7.2.3.
By Route (Intravenous, Oral, Subcutaneous, Topical)
7.2.4. By Distribution Channel (Hospital Pharmacies, Retail
Pharmacies, Online Pharmacies)
7.2.5. By Country
7.3. Europe: Country Analysis
7.3.1. Germany Direct-acting Antiviral Drug Market Outlook
7.3.1.1.
Market Size &
Forecast
7.3.1.1.1.
By Value
7.3.1.2.
Market Share &
Forecast
7.3.1.2.1.
By Drug Type
7.3.1.2.2.
By Indication
7.3.1.2.3.
By Route
7.3.1.2.4.
By Distribution
Channel
7.3.2. United Kingdom Direct-acting Antiviral Drug Market Outlook
7.3.2.1.
Market Size &
Forecast
7.3.2.1.1.
By Value
7.3.2.2.
Market Share &
Forecast
7.3.2.2.1.
By Drug Type
7.3.2.2.2.
By Indication
7.3.2.2.3.
By Route
7.3.2.2.4.
By Distribution
Channel
7.3.3. France Direct-acting Antiviral Drug Market Outlook
7.3.3.1.
Market Size &
Forecast
7.3.3.1.1.
By Value
7.3.3.2.
Market Share &
Forecast
7.3.3.2.1.
By Drug Type
7.3.3.2.2.
By Indication
7.3.3.2.3.
By Route
7.3.3.2.4.
By Distribution
Channel
7.3.4. Italy Direct-acting Antiviral Drug Market Outlook
7.3.4.1.
Market Size &
Forecast
7.3.4.1.1.
By Value
7.3.4.2.
Market Share &
Forecast
7.3.4.2.1.
By Drug Type
7.3.4.2.2.
By Indication
7.3.4.2.3.
By Route
7.3.4.2.4.
By Distribution
Channel
7.3.5. Spain Direct-acting Antiviral Drug Market Outlook
7.3.5.1.
Market Size &
Forecast
7.3.5.1.1.
By Value
7.3.5.2.
Market Share &
Forecast
7.3.5.2.1.
By Drug Type
7.3.5.2.2.
By Indication
7.3.5.2.3.
By Route
7.3.5.2.4.
By Distribution
Channel
8.
Asia-Pacific Direct-acting
Antiviral Drug Market Outlook
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1.
By Type (NS3/4A Protease, NS5A Protein, NS5B RNA-Dependent
RNA polymerase)
8.2.2.
By Indication (Hepatitis C Virus, HIV Infection/ AIDS, Influenza,
Prophylaxis)
8.2.3.
By Route (Intravenous, Oral, Subcutaneous, Topical)
8.2.4. By Distribution Channel (Hospital Pharmacies, Retail
Pharmacies, Online Pharmacies)
8.2.5. By Country
8.3. Asia-Pacific: Country Analysis
8.3.1. China Direct-acting Antiviral Drug Market Outlook
8.3.1.1.
Market Size &
Forecast
8.3.1.1.1.
By Value
8.3.1.2.
Market Share &
Forecast
8.3.1.2.1.
By Drug Type
8.3.1.2.2.
By Indication
8.3.1.2.3.
By Route
8.3.1.2.4.
By Distribution
Channel
8.3.2. Japan Direct-acting Antiviral Drug Market Outlook
8.3.2.1.
Market Size &
Forecast
8.3.2.1.1.
By Value
8.3.2.2.
Market Share &
Forecast
8.3.2.2.1.
By Drug Type
8.3.2.2.2.
By Indication
8.3.2.2.3.
By Route
8.3.2.2.4.
By Distribution
Channel
8.3.3. India Direct-acting Antiviral Drug Market Outlook
8.3.3.1.
Market Size &
Forecast
8.3.3.1.1.
By Value
8.3.3.2.
Market Share &
Forecast
8.3.3.2.1.
By Drug Type
8.3.3.2.2.
By Indication
8.3.3.2.3.
By Route
8.3.3.2.4.
By Distribution
Channel
8.3.4. Australia Direct-acting Antiviral Drug Market Outlook
8.3.4.1.
Market Size &
Forecast
8.3.4.1.1.
By Value
8.3.4.2.
Market Share &
Forecast
8.3.4.2.1.
By Drug Type
8.3.4.2.2.
By Indication
8.3.4.2.3.
By Route
8.3.4.2.4.
By Distribution
Channel
8.3.5. South Korea Direct-acting Antiviral Drug Market Outlook
8.3.5.1.
Market Size &
Forecast
8.3.5.1.1.
By Value
8.3.5.2.
Market Share &
Forecast
8.3.5.2.1.
By Drug Type
8.3.5.2.2.
By Indication
8.3.5.2.3.
By Route
8.3.5.2.4.
By Distribution
Channel
9.
South America Direct-acting
Antiviral Drug Market Outlook
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1.
By Type (NS3/4A Protease, NS5A Protein, NS5B
RNA-Dependent RNA polymerase)
9.2.2.
By Indication (Hepatitis C Virus, HIV Infection/ AIDS, Influenza,
Prophylaxis)
9.2.3.
By Route (Intravenous, Oral, Subcutaneous, Topical)
9.2.4. By Distribution Channel (Hospital Pharmacies, Retail
Pharmacies, Online Pharmacies)
9.2.5. By Country
9.3. South America: Country Analysis
9.3.1. Brazil Direct-acting Antiviral Drug Market Outlook
9.3.1.1.
Market Size &
Forecast
9.3.1.1.1.
By Value
9.3.1.2.
Market Share &
Forecast
9.3.1.2.1.
By Drug Type
9.3.1.2.2.
By Indication
9.3.1.2.3.
By Route
9.3.1.2.4.
By Distribution
Channel
9.3.2. Argentina Direct-acting Antiviral Drug Market Outlook
9.3.2.1.
Market Size &
Forecast
9.3.2.1.1.
By Value
9.3.2.2.
Market Share &
Forecast
9.3.2.2.1.
By Drug Type
9.3.2.2.2.
By Indication
9.3.2.2.3.
By Route
9.3.2.2.4.
By Distribution
Channel
9.3.3. Colombia Direct-acting Antiviral Drug Market Outlook
9.3.3.1.
Market Size &
Forecast
9.3.3.1.1.
By Value
9.3.3.2.
Market Share &
Forecast
9.3.3.2.1.
By Drug Type
9.3.3.2.2.
By Indication
9.3.3.2.3.
By Route
9.3.3.2.4.
By Distribution
Channel
10.
Middle East and
Africa Direct-acting Antiviral Drug Market Outlook
10.1.
Market Size &
Forecast
10.1.1. By Value
10.2.
Market Share &
Forecast
10.2.1.
By Type (NS3/4A Protease, NS5A Protein, NS5B
RNA-Dependent RNA polymerase)
10.2.2.
By Indication (Hepatitis C Virus, HIV Infection/ AIDS, Influenza,
Prophylaxis)
10.2.3.
By Route (Intravenous, Oral, Subcutaneous, Topical)
10.2.4. By Distribution Channel (Hospital Pharmacies, Retail
Pharmacies, Online Pharmacies)
10.2.5. By Country
10.3.
MEA: Country
Analysis
10.3.1. South Africa Direct-acting Antiviral Drug Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1.
By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1.
By Drug Type
10.3.1.2.2.
By Indication
10.3.1.2.3.
By Route
10.3.1.2.4.
By Distribution
Channel
10.3.2. Saudi Arabia Direct-acting Antiviral Drug Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1.
By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1.
By Drug Type
10.3.2.2.2.
By Indication
10.3.2.2.3.
By Route
10.3.2.2.4.
By Distribution
Channel
10.3.3. UAE Direct-acting Antiviral Drug Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1.
By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1.
By Drug Type
10.3.3.2.2.
By Indication
10.3.3.2.3.
By Route
10.3.3.2.4.
By Distribution
Channel
10.3.4. Kuwait Direct-acting Antiviral Drug Market Outlook
10.3.4.1. Market Size & Forecast
10.3.4.1.1.
By Value
10.3.4.2. Market Share & Forecast
10.3.4.2.1.
By Drug Type
10.3.4.2.2.
By Indication
10.3.4.2.3.
By Route
10.3.4.2.4.
By Distribution
Channel
11. Market Dynamics
11.1.
Drivers
11.2.
Challenges
12. Market Trends & Developments
12.1.
Recent Development
12.2.
Mergers &
Acquisitions
12.3.
Product Launches
13.
Porter’s Five Forces Analysis
13.1.
Competition in the
Industry
13.2.
Potential of New
Entrants
13.3.
Power of Suppliers
13.4.
Power of Customers
13.5.
Threat of Substitute
Products
14. Competitive Landscape
14.1.
Business Overview
14.2.
Product Offerings
14.3.
Recent Developments
14.4.
Financials (As Reported)
14.5.
Key Personnel
14.6.
SWOT Analysis
14.6.1. Natco Pharma Ltd
14.6.2. Vertex
Pharmaceuticals Inc
14.6.3. Dr Reddy's Laboratories
Ltd
14.6.4. Johnson &
Johnson
14.6.5. Merck & Co Inc
14.6.6. Gilead Sciences Inc
14.6.7. AbbVie Inc
14.6.8. Bristol-Myers Squibb
Co
15. Strategic Recommendations
16.
About Us & Disclaimer